Allergan PLC. (NYSE:AGN) received a $288.00 price target from investment analysts at Credit Suisse Group in a report issued on Saturday. The firm currently has a “buy” rating on the stock. Credit Suisse Group’s price target would indicate a potential upside of 18.69% from the company’s previous close.
AGN has been the subject of a number of other research reports. UBS AG reiterated a “buy” rating and set a $275.00 target price on shares of Allergan PLC. in a research report on Monday, May 15th. Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price for the company in a research report on Monday, June 26th. Royal Bank Of Canada set a $284.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Monday, June 12th. BidaskClub upgraded shares of Allergan PLC. from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Finally, Mizuho reiterated a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a research report on Wednesday. Seven analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Allergan PLC. presently has a consensus rating of “Buy” and a consensus target price of $274.14.
Allergan PLC. (NYSE:AGN) opened at 242.65 on Friday. The firm’s 50-day moving average is $245.21 and its 200-day moving average is $237.12. The firm has a market capitalization of $81.50 billion, a price-to-earnings ratio of 7.56 and a beta of 1.16. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.25%. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the company posted $3.35 EPS. On average, equities analysts anticipate that Allergan PLC. will post $16.10 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This story was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://stocknewstimes.com/2017/08/06/allergan-plc-agn-given-a-288-00-price-target-at-credit-suisse-group.html.
In related news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.36% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGN. Crestwood Advisors Group LLC acquired a new position in Allergan PLC. during the first quarter valued at approximately $103,000. Feltz Wealth PLAN Inc. acquired a new position in Allergan PLC. during the first quarter valued at approximately $107,000. Enterprise Financial Services Corp raised its position in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares during the period. Jacobi Capital Management LLC raised its position in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares during the period. Finally, JNBA Financial Advisors raised its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the period. 84.66% of the stock is currently owned by institutional investors and hedge funds.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.
